Literature DB >> 10543270

Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease.

A G Agustí1, J M Villaverde, B Togores, M Bosch.   

Abstract

Excessive inflammation seems important in chronic obstructive pulmonary disease (COPD), particularly during exacerbations of the disease. Exhaled nitric oxide concentration ([NOexh]) is a sensitive marker of bronchial inflammation in asthma; it is unclear if this is also the case in COPD. This study: 1) quantifies [NOexh] in patients with COPD (during an exacerbation and while clinically stable); 2) investigates the response of [NOexh] to i.v. steroid therapy, and its potential relationship with other relevant physiological variables; and 3) assesses the relative contributions of the central and peripheral airways to [NOexh] by collecting exhaled air in two different bags connected in series. Seventeen COPD patients (forced expiratory volume in one second (FEV1) 37.6+/-3.4% of the predicted value (+/-SEM)) hospitalized because of an exacerbation of the disease (arterial oxygen tension (Pa,O2) (7.46+/-0.72 kPa 56.1+/-5.4 mmHg), arterial carbon dioxide tension (Pa,CO2) 5.63+/-0.37 kPa 42.3+/-2.8 mmHg), pH 7.41+/-0.02) and 10 healthy subjects that served as controls were studied. On admission, [NOexh] in COPD was higher than normal (41.0+/-5.1 versus 13.3+/-0.8 parts per billion (ppb), respectively, p<0.001). Despite i.v. steroid therapy, [NOexh] remained elevated throughout recovery (37.9+/-4.8 ppb, p<0.001) until discharge (40.9+/-4.3 ppb, p<0.001). In contrast, when the patients were clinically stable (several months later), [NOexh] was significantly reduced (15.8+/-3.8 ppb, p<0.001), and no longer different from control values. [NOexh] was not related to any of the physiological variables measured during recovery (pulmonary gas exchange) or at discharge (forced spirometry, lung volumes, diffusing capacity). Finally, the contribution of the central and peripheral airways to [NOexh] was not different at any point in time. These results indicate that during exacerbations of chronic obstructive pulmonary disease, the exhaled nitric oxide concentration: 1) is higher than normal; 2) is not reduced acutely by i.v. steroids but is normalized several months after discharge; 3) is unrelated to several physiological indices of disease severity; and 4) appears to be produced homogeneously in central and peripheral airways. Overall, these results are different from those reported in asthma, suggesting that different inflammatory mechanisms are operating in both diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543270     DOI: 10.1034/j.1399-3003.1999.14c08.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  25 in total

1.  Tidal lung recruitment and exhaled nitric oxide during coronary artery bypass grafting in patients with and without chronic obstructive pulmonary disease.

Authors:  Alysson R Carvalho; Fumito Ichinose; Ivany A Schettino; Dean Hess; Javier Rojas; Antonio Giannella-Neto; Arvind Agnihotri; Jennifer Walker; Thomas E MacGillivray; Marcos F Vidal Melo
Journal:  Lung       Date:  2011-09-28       Impact factor: 2.584

2.  Nitrite in exhaled breath condensate as a marker of nitrossative stress in the airways of patients with asthma, COPD, and idiopathic pulmonary fibrosis.

Authors:  Vladimír Rihák; Petr Zatloukal; Jirina Chládková; Alena Zimulová; Zuzana Havlínová; Jaroslav Chládek
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

3.  Biomarkers of systemic inflammation in stable and exacerbation phases of COPD.

Authors:  Fisun Karadag; Aslihan B Karul; Orhan Cildag; Mustafa Yilmaz; Hatice Ozcan
Journal:  Lung       Date:  2008-09-20       Impact factor: 2.584

Review 4.  Exhaled nitric oxide measurements: clinical application and interpretation.

Authors:  D R Taylor; M W Pijnenburg; A D Smith; J C De Jongste
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

5.  Effect of pulmonary rehabilitation on exhaled nitric oxide in patients with chronic obstructive pulmonary disease.

Authors:  E Clini; L Bianchi; K Foglio; R Porta; M Vitacca; N Ambrosino
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

6.  Use of Exhaled Nitric Oxide as a Biomarker in Diagnosis and Management of Chronic Obstructive Pulmonary Disease.

Authors:  Ahmed A Arif; Colin Mitchell
Journal:  J Prim Care Community Health       Date:  2015-12-30

7.  Exhaled nitric oxide in stable chronic obstructive pulmonary disease.

Authors:  Mohammed F S Beg; Mohammad A Alzoghaibi; Abdullah A Abba; Syed S Habib
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

Review 8.  Multiple roles of nitric oxide in the airways.

Authors:  F L M Ricciardolo
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

9.  Randomized placebo controlled assessment of airway inflammation due to racemic albuterol and levalbuterol via exhaled nitric oxide testing.

Authors:  John F Freiler; Rajiv Arora; Thomas C Kelley; Larry Hagan; Patrick F Allan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Clinical use of exhaled biomarkers in COPD.

Authors:  Philip O'Reilly; William Bailey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.